<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04362111</url>
  </required_header>
  <id_info>
    <org_study_id>Chatham-Cytokine Covid-19</org_study_id>
    <nct_id>NCT04362111</nct_id>
  </id_info>
  <brief_title>Early Identification and Treatment of Cytokine Storm Syndrome in Covid-19</brief_title>
  <official_title>Early Identification and Treatment of Cytokine Storm Syndrome in Covid-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This proposal addresses the problem of preventing the very high mortality and morbidity
      associated with the development of Cytokine Storm Syndrome (CSS) associated respiratory
      failure in Covid-19 infection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The first aim of this project is to determine whether rapidly assayed early clinical
      laboratory markers of CSS (eCSS: leucopenia, lymphopenia, and elevated ferritin, d-dimer,
      LDH, CRP, and AST/ALT) in patients admitted to the hospital with respiratory compromise in
      the setting of Covid-19 infection can accurately identify patients with CSS as defined by
      validated CSS case definitions (H-Score, aHLH-2004). Confirmation of eCSS predictive of
      evolving CSS will identify patients at risk for rapid deterioration of lung function and
      inform early initiation of treatment for CSS. Genotyping studies will also be performed on
      patients with confirmed CSS to determine whether perforin pathway mutations commonly present
      in CSS associated with other disorders are present. The second aim is to determine whether
      early treatment with rhIL-1Ra (anakinra) in patients admitted to the hospital with markers of
      CSS improves or prevents deterioration of respiratory dysfunction and prevents the
      development of respiratory failure requiring mechanical ventilation.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2020</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">July 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Two parallel treatment arms. Subjects failing primary outcome will be unblinded and can then receive open label anakinra</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Investigator, care provider, and participant blinded until primary outcome assessed; non-responders in placebo arm may cross-over to open-label anakinra</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>No increase in oxygen requirement and no increase in respiratory support measures</measure>
    <time_frame>48 hours</time_frame>
    <description>Supplemental oxygen requirement to maintain oxygen saturation &gt;90% stable or decreased without escalation of respiratory measures (addition of CPAP, initiation of mechanical ventilation)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement in Cytokine Storm markers</measure>
    <time_frame>72 hours</time_frame>
    <description>25% decrease in noted baseline elevations of serum ferritin, LDH, CRP, and d-dimer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>No requirement for mechanical ventilation</measure>
    <time_frame>Day 5 (120 hours)</time_frame>
    <description>Subjects discharged from hospital without the need for mechanical ventilation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Cytokine Storm</condition>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Anakinra Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The active treatment group will receive anakinra 100 mg subcutaneously every 6 hours for period of 5 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The control group will receive normal saline placebo subcutaneously every 6 hours for period of 5 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anakinra</intervention_name>
    <description>The active treatment group will receive anakinra 100 mg subcutaneously every 6 hours for period of 5 days.</description>
    <arm_group_label>Anakinra Group</arm_group_label>
    <other_name>recombinant human IL-ra (rhIL-1ra)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline</intervention_name>
    <description>The control group will receive normal saline placebo subcutaneously every 6 hours for period of 5 days.</description>
    <arm_group_label>Control Group</arm_group_label>
    <other_name>NS</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 18 years old or older

          2. Molecular (pcRNA) diagnosis of SARS-CoV-2 infection

          3. Hyperferritinemia (&gt;700 ng/ml)

          4. Fever &gt;38 degrees C

          5. Any two of the following:

               1. Elevated d-dimer (&gt; 500 ng/ml) or thrombocytopenia (&lt; 130,000/mm3)

               2. leucopenia (WBC &lt;3500/mm3) or lymphopenia (&lt;1000/mm3)

               3. elevated AST or ALT (&gt; 2X ULN)

               4. elevated LDH (&gt; 2X ULN)

        Exclusion Criteria:

          1. Participation in other investigational treatment protocols for Covid-19 infection

          2. Culture confirmed active bacterial infection requiring antibiotic therapy

          3. On mechanical ventilation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Walter W Chatham, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Walter W Chatham, MD</last_name>
    <phone>800-822-6478</phone>
    <email>wchatham@uabmc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Angela Kendrach</last_name>
    <phone>205-996-5602</phone>
    <email>akendrach@uab.edu</email>
  </overall_contact_backup>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 21, 2020</study_first_submitted>
  <study_first_submitted_qc>April 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 24, 2020</study_first_posted>
  <last_update_submitted>April 23, 2020</last_update_submitted>
  <last_update_submitted_qc>April 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alabama at Birmingham</investigator_affiliation>
    <investigator_full_name>W Winn Chatham</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interleukin 1 Receptor Antagonist Protein</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Contact PI by e-mail for protocol specifics Submission of results for peer reviewed publication</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>During study enrollment</ipd_time_frame>
    <ipd_access_criteria>wchatham@uabmc.edu</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

